Contact Us
Drug Search Results
More Filters [+]

AG-013

Alternative Names: ag-013, ag013, ag 013
Latest Update: 2020-10-05
Latest Update Note: Clinical Trial Update

Product Description

AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis).

Mechanisms of Action: Angiogenesis Inhibitor,VEGFR Inhibitor

Novel Mechanism: No

Modality: Nondrug

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Oragenics
Company Location: TAMPA FL 33634
Company CEO: Kimberly Murphy
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AG-013

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Mucositis|Stomatitis|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Colorectal Cancer

Phase 1: Head and Neck Cancer|Stomatitis|Mucositis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2016-004161-68

P2

Completed

Head and Neck Cancer|Mucositis

2020-07-02

AG013-ODOM-201

P2

Terminated

Stomatitis|Mucositis

2020-03-31

24%
SENSOR

P2

Completed

Non-Small-Cell Lung Cancer|Colorectal Cancer

2019-03-19

AG013-ODOM-101

P1

Completed

Mucositis|Stomatitis|Head and Neck Cancer

2012-09-01

Recent News Events

Date

Type

Title

07/10/2020

News Article

 Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program

04/15/2020

News Article

 Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer

12/02/2019

News Article

 Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

10/22/2019

News Article

 Oragenics, Inc. to Present at the BIO Investor Forum

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions